In last trading session, Organogenesis Holdings Inc (NASDAQ:ORGO) saw 0.76 million shares changing hands with its beta currently measuring 1.76. Company’s recent per share price level of $3.01 trading at -$0.12 or -3.83% at ring of the bell on the day assigns it a market valuation of $378.43M. That closing price of ORGO’s stock is at a discount of -51.83% from its 52-week high price of $4.57 and is indicating a premium of 28.24% from its 52-week low price of $2.16. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.48 million shares which gives us an average trading volume of 724.56K if we extend that period to 3-months.

For Organogenesis Holdings Inc (ORGO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.02 in the current quarter.

Organogenesis Holdings Inc (NASDAQ:ORGO) trade information

Upright in the red during last session for losing -3.83%, in the last five days ORGO remained trading in the red while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $3.01 price level, adding 7.1% to its value on the day. Organogenesis Holdings Inc’s shares saw a change of -5.94% in year-to-date performance and have moved -0.66% in past 5-day. Organogenesis Holdings Inc (NASDAQ:ORGO) showed a performance of -14.00% in past 30-days. Number of shares sold short was 11.0 million shares which calculate 9.69 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 39.8% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -66.11% in reaching the projected high whereas dropping to the targeted low would mean a loss of -66.11% for stock’s current value.

Organogenesis Holdings Inc (ORGO) estimates and forecasts

Statistics highlight that Organogenesis Holdings Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 2.03% of value to its shares in past 6 months, showing an annual growth rate of -275.00% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 7.50% from the last financial year’s standing.

3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 109.6M for the same. And 1 analysts are in estimates of company making revenue of 114.7M in the next quarter. Company posted 99.65M and 109.98M of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around -174.65% while estimates for its earnings growth in next 5 years are of 2.41%.

Organogenesis Holdings Inc (NASDAQ:ORGO)’s Major holders

Insiders are in possession of 45.96% of company’s total shares while institution are holding 50.88 percent of that, with stock having share float percentage of 94.16%. Investors also watch the number of corporate investors in a company very closely, which is 50.88% institutions for Organogenesis Holdings Inc that are currently holding shares of the company. MORGAN STANLEY is the top institutional holder at ORGO for having 11.58 million shares of worth $32.41 million. And as of 2024-06-30, it was holding 8.7789 of the company’s outstanding shares.

The second largest institutional holder is SOLEUS CAPITAL MANAGEMENT, L.P., which was holding about 11.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.7356 of outstanding shares, having a total worth of $32.25 million.

On the other hand, iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 1.94 shares of worth $5.83 million or 1.54% of the total outstanding shares. The later fund manager was in possession of 1.59 shares on Sep 30, 2024 , making its stake of worth around $4.78 million in the company or a holder of 1.26% of company’s stock.